Effects of the enlargement of polyglutamine segments on the structure and folding of ataxin-2 and ataxin-3 proteins

Spinocerebellar ataxia type 2 (SCA2) and type 3 (SCA3) are two common autosomal-dominant inherited ataxia syndromes, both of which are related to the unstable expansion of trinucleotide CAG repeats in the coding region of the related ATXN2 and ATXN3 genes, respectively. The poly-glutamine (poly-Q) tract encoded by the CAG repeats has long been recognized as an important factor in disease pathogenesis and progress. In this study, using the I-TASSER method for 3D structure prediction, we investigated the effect of poly-Q tract enlargement on the structure and folding of ataxin-2 and ataxin-3 proteins. Our results show good agreement with the known experimental structures of the Josephin and UIM domains providing credence to the simulation results presented here, which show that the enlargement of the poly-Q region not only affects the local structure of these regions but also affects the structures of functional domains as well as the whole protein. The changes observed in the predicted models of the UIM domains in ataxin-3 when the poly-Q track is enlarged provide new insights on possible pathogenic mechanisms.

[1]  Feng Ding,et al.  Polyglutamine Induced Misfolding of Huntingtin Exon1 is Modulated by the Flanking Sequences , 2010, PLoS Comput. Biol..

[2]  J. Skolnick,et al.  TM-align: a protein structure alignment algorithm based on the TM-score , 2005, Nucleic acids research.

[3]  Zbyszek Otwinowski,et al.  Secondary structure of Huntingtin amino-terminal region. , 2009, Structure.

[4]  Pawel Sikorski,et al.  New model for crystalline polyglutamine assemblies and their connection with amyloid fibrils. , 2005, Biomacromolecules.

[5]  Thomas Lengauer,et al.  Structural and functional analysis of ataxin-2 and ataxin-3. , 2004, European journal of biochemistry.

[6]  J T Finch,et al.  Amyloid fibers are water-filled nanotubes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[7]  I. Kanazawa,et al.  Abnormal gene product identified in hereditary dentatorubral–pallidoluysian atrophy (DRPLA) brain , 1995, Nature Genetics.

[8]  Xue Gao,et al.  Structural Transformation of the Tandem Ubiquitin-Interacting Motifs in Ataxin-3 and Their Cooperative Interactions with Ubiquitin Chains , 2010, PloS one.

[9]  L. Velázquez-Pérez,et al.  Spinocerebellar Ataxia Type 2: Clinical Presentation, Molecular Mechanisms, and Therapeutic Perspectives , 2012, Molecular Neurobiology.

[10]  Pier Paolo Di Fiore,et al.  Deubiquitinating function of ataxin-3: insights from the solution structure of the Josephin domain. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[11]  C. Roland,et al.  Structural determinants of polyglutamine protofibrils and crystallites. , 2015, ACS chemical neuroscience.

[12]  W. Kabsch,et al.  Dictionary of protein secondary structure: Pattern recognition of hydrogen‐bonded and geometrical features , 1983, Biopolymers.

[13]  M. Diamond,et al.  Polyglutamine diseases: emerging concepts in pathogenesis and therapy. , 2007, Human molecular genetics.

[14]  Daniel R. Scoles,et al.  Consensus Paper: Pathological Mechanisms Underlying Neurodegeneration in Spinocerebellar Ataxias , 2013, The Cerebellum.

[15]  M. Engelhard,et al.  Structural characterization of polyglutamine fibrils by solid-state NMR spectroscopy. , 2011, Journal of molecular biology.

[16]  Julio C. Facelli,et al.  Structure prediction of polyglutamine disease proteins: comparison of methods , 2014, BMC Bioinformatics.

[17]  C. Richter,et al.  Calpain-mediated ataxin-3 cleavage in the molecular pathogenesis of spinocerebellar ataxia type 3 (SCA3). , 2013, Human molecular genetics.

[18]  V. Volpini,et al.  The spinocerebellar ataxias: clinical aspects and molecular genetics. , 2012, Advances in experimental medicine and biology.

[19]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[20]  Meewhi Kim.  Pathogenic polyglutamine expansion length correlates with polarity of the flanking sequences , 2014, Molecular Neurodegeneration.

[21]  O. Onodera,et al.  Amino acid sequences flanking polyglutamine stretches influence their potential for aggregate formation , 2001, Neuroreport.

[22]  Y. Agid,et al.  Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion , 1997, Nature Genetics.

[23]  Georg Auburger,et al.  Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2 , 1996, Nature Genetics.

[24]  P. Tompa.  Intrinsically unstructured proteins. , 2002, Trends in biochemical sciences.

[25]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[26]  G. Crooks,et al.  WebLogo: a sequence logo generator. , 2004, Genome research.

[27]  Reinhard Pahl,et al.  Flanking polyproline sequences inhibit beta-sheet structure in polyglutamine segments by inducing PPII-like helix structure. , 2007, Journal of molecular biology.

[28]  Y. Chern,et al.  Conformational switch of polyglutamine-expanded huntingtin into benign aggregates leads to neuroprotective effect , 2015, Scientific Reports.

[29]  Yang Zhang,et al.  I-TASSER: a unified platform for automated protein structure and function prediction , 2010, Nature Protocols.

[30]  Huda Y. Zoghbi,et al.  Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1 , 1993, Nature Genetics.

[31]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[32]  T. Bird,et al.  Late-onset SCA2: 33 CAG repeats are sufficient to cause disease , 2000, Neurology.

[33]  Yoshiki Yamaguchi,et al.  Mode of substrate recognition by the Josephin domain of ataxin‐3, which has an endo‐type deubiquitinase activity , 2014, FEBS letters.

[34]  S. Pulst,et al.  Genetic Variance in the Spinocerebellar Ataxia Type 2 (ATXN2) Gene in Children with Severe Early Onset Obesity , 2009, PloS one.

[35]  John Q. Trojanowski,et al.  Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS , 2010, Nature.

[36]  Q. Pan,et al.  Frequency of SCA1, SCA2, SCA3/MJD, SCA6, SCA7, and DRPLA CAG trinucleotide repeat expansion in patients with hereditary spinocerebellar ataxia from Chinese kindreds. , 2000, Archives of neurology.

[37]  Andreas Vitalis,et al.  Atomistic simulations of the effects of polyglutamine chain length and solvent quality on conformational equilibria and spontaneous homodimerization. , 2008, Journal of molecular biology.

[38]  R. Murphy,et al.  Location trumps length: polyglutamine-mediated changes in folding and aggregation of a host protein. , 2011, Biophysical journal.

[39]  Shigenobu Nakamura,et al.  CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1 , 1994, Nature Genetics.

[40]  O. Quarrell.  Glutamine repeats and neurodegenerative diseases: molecular aspects , 2001, Human Genetics.

[41]  Dalaver H. Anjum,et al.  Polyglutamine disruption of the huntingtin exon1 N-terminus triggers a complex aggregation mechanism , 2009, Nature Structural &Molecular Biology.

[42]  Gregory A Voth,et al.  Molecular dynamics simulations of polyglutamine aggregation using solvent-free multiscale coarse-grained models. , 2010, The journal of physical chemistry. B.

[43]  E. Papaleo,et al.  The conformational ensemble of the disordered and aggregation-protective 182-291 region of ataxin-3. , 2013, Biochimica et biophysica acta.

[44]  Markus S Miettinen,et al.  Assessing polyglutamine conformation in the nucleating event by molecular dynamics simulations. , 2012, The journal of physical chemistry. B.

[45]  Marek Cieplak,et al.  An Exploration of the Universe of Polyglutamine Structures , 2015, PLoS Comput. Biol..

[46]  H. Paulson,et al.  Caspase‐mediated proteolysis of the polyglutamine disease protein ataxin‐3 , 2004, Journal of neurochemistry.

[47]  S. W. Davies,et al.  Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. , 1997, Science.

[48]  I. Guzhova,et al.  Pharmacological protein targets in polyglutamine diseases: Mutant polypeptides and their interactors , 2013, FEBS letters.

[49]  Yang Zhang,et al.  Scoring function for automated assessment of protein structure template quality , 2004, Proteins.

[50]  Meewhi Kim,et al.  Beta conformation of polyglutamine track revealed by a crystal structure of Huntingtin N-terminal region with insertion of three histidine residues , 2013, Prion.

[51]  Juan J de Pablo,et al.  Structural motif of polyglutamine amyloid fibrils discerned with mixed-isotope infrared spectroscopy , 2014, Proceedings of the National Academy of Sciences.

[52]  Giuseppe Nicastro,et al.  The solution structure of the Josephin domain of ataxin-3: structural determinants for molecular recognition. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[53]  S. Kügler,et al.  Calpastatin-mediated inhibition of calpains in the mouse brain prevents mutant ataxin 3 proteolysis, nuclear localization and aggregation, relieving Machado-Joseph disease. , 2012, Brain : a journal of neurology.

[54]  Z. Ou-Yang,et al.  Concentration and temperature dependences of polyglutamine aggregation by multiscale coarse-graining molecular dynamics simulations. , 2012, The journal of physical chemistry. B.

[55]  G. Kozlov,et al.  Structural Basis of Binding of P-body-associated Proteins GW182 and Ataxin-2 by the Mlle Domain of Poly(A)-binding Protein* , 2010, The Journal of Biological Chemistry.